Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 11, 2011, Pages 1604-1611

  Miyahara, Koji ^a   Nouso, Kazuhiro ^a   Tomoda, Takeshi ^a   Kobayashi, Sayo ^a   Hagihara, Hiroaki ^a   Kuwaki, Kenji ^a   Toshimori, Junichi ^a   Onishi, Hideki ^a   Ikeda, Fusao ^a   Miyake, Yasuhiro ^a   Nakamura, Shinichiro ^a   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Biomarker; Cytokine; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ANGIOPOIETIN 2; CD31 ANTIGEN; CYTOKINE; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LEPTIN; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; SORAFENIB; VASCULOTROPIN;

AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 80054954581     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06887.x     Document Type: Article

References (38)

1. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 2005; 40: 225-35.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA. Cancer J. Clin. 2005; 55: 74-108.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
5. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35: 421-30.
6. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
7. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
8. Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006; 24: 4293-300.
9. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205-16.
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010; 30: 52-60.
11. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006; 242: 151-67.
12. Llovet J, Pena C, Shan M, Jeffers M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with hepatocellular carcinoma: results from the randomized phase iii sharp trial. Hepatology 2008; 48 (Suppl.): 372A (AASLD 2008, abstr#149).
13. Zhu AX, Sahani DV, Duda DG etal. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009; 27: 3027-35.
14. Burstein HJ, Chen YH, Parker LM etal. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin. Cancer Res. 2008; 14: 7871-7.
15. Jubb AM, Hurwitz HI, Bai W etal. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 2006; 24: 217-27.
16. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 2008; 14: 1407-12.
17. Peña C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from the Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin. Cancer Res. 2010; 16: 4853-63.
18. Chao Y, Li CP, Chau GY etal. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 2003; 10: 355-62.
19. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 2004; 91: 1354-60.
20. Kim SJ, Choi IK, Park KH etal. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn. J. Clin. Oncol. 2004; 34: 184-90.
21. Jeng KS, Sheen IS, Wang YC etal. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol. 2004; 10: 643-8.
22. Vejchapipat P, Tangkijvanich P, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J. Gastroenterol. 2004; 39: 1182-8.
23. Czochra P, Kutzner P, Maass T etal. Accelerated tumor progression in chemical carcinogenesis model in PDGF-B transgenic mice. Hepatology 2006; 44 (Suppl. 1): A122.
24. Maass T, Thieringer FR, Mann A etal. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int. J. Cancer 2011; 128: 1259-68.
25. Mitsuhashi N, Shimizu H, Ohtsuka M etal. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-13.
26. Torimura T, Ueno T, Kin M etal. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J. Hepatol. 2004; 40: 799-807.
27. Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J. Gastroenterol. 2006; 12: 4241-5.
28. Moon WS, Rhyu KH, Kang MJ etal. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod. Pathol. 2003; 16: 552-7.
29. Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E, Vacca A. Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides 2008; 29: 1596-602.
30. Fukunaga R, Seto Y, Mizushima S, Nagata S. Three different mRNAs encoding human granulocyte colony-stimulating factor receptor. Proc. Natl. Acad. Sci. U.S.A. 1990; 87: 8702-6.
31. Wang SY, Chen LY, Tsai TF, Su TS, Choo KB, Ho CK. Constitutive production of colony-stimulating factors by human hepatoma cell lines: possible correlation with cell differentiation. Exp. Hematol. 1996; 24: 437-44.
32. Araki K, Kishihara F, Takahashi K etal. Hepatocellular carcinoma producing a granulocyte colony-stimulating factor: report of a resected case with a literature review. Liver Int. 2007; 27: 716-21.
33. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 2640-5.
34. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim. Biophys. Acta 2010; 1806: 18-28.
35. Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol. Vis. 2009; 15: 1906-14.
36. Yilmaz Y, Yonal O, Kurt R etal. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Arch. Med. Res. 2011; 42: 38-43.
37. Zhang BB, Cai WM, Weng HL etal. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J. Gastroenterol. 2003; 9: 2490-6.
38. Cenni E, Fotia C, Rustemi E etal. Idiopathic and secondary osteonecrosis of the femoral head show different thrombophilic changes and normal or higher levels of platelet growth factors. Acta Orthop. 2011; 82: 42-9.